top of page

Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease

Laura Sepp-Lorenzino, Ph.D., Executive Vice President, Chief Scientific Officer, Intellia Therapeutics



Laura Sepp-Lorenzino, Ph.D. oversees all platform and pipeline research activities at Intellia Therapeutics in her role as Chief Scientific Officer. Intellia’s leading CRISPR/Cas9-based platform supports a full-spectrum strategy, which deploys differentiated, modular solutions across in vivo and ex vivo therapeutic applications. Before joining Intellia, Laura was VP, Head of Nucleic Acid Therapies and member of the External Innovation team at Vertex Pharmaceuticals, with previous positions as VP and entrepreneur-in-residence at Alnylam Pharmaceuticals, Inc., and Executive Director RNA Therapeutics at Merck & Co., Inc. In addition to her extensive experience in nucleic acid therapies, Laura has expertise in oncology drug discovery and development acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as an assistant attending molecular biologist at Memorial Sloan-Kettering Cancer Center. She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her M.S. and Ph.D. in Biochemistry from New York University. Laura is a member of Taysha Gene Therapies’ board of directors and sits on the scientific advisory board of Thermo Fisher Scientific, Lodo Therapeutics, the U.K. Nucleic Acid Therapy Accelerator.


Comments


bottom of page